• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative.

作者信息

Azuma Hiroshi, Amano Toraji, Kamiyama Naoya, Takehara Naofumi, Jingu Maki, Takagi Harumi, Sugita Osamu, Kobayashi Naoko, Kure Tomoko, Shimizu Taro, Ishida Tatsuhiro, Matsumoto Masanori, Sakai Hiromi

机构信息

Department of Pediatrics, Asahikawa Medical University, Asahikawa, Japan.

Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.

出版信息

Blood Adv. 2022 Nov 8;6(21):5711-5715. doi: 10.1182/bloodadvances.2022007977.

DOI:10.1182/bloodadvances.2022007977
PMID:35939788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9618780/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/4b23858ce55c/BLOODA_ADV-2022-007977-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/33c165ffe07a/BLOODA_ADV-2022-007977-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/f5c1e903eed8/BLOODA_ADV-2022-007977-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/4b23858ce55c/BLOODA_ADV-2022-007977-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/33c165ffe07a/BLOODA_ADV-2022-007977-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/f5c1e903eed8/BLOODA_ADV-2022-007977-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f83d/9618780/4b23858ce55c/BLOODA_ADV-2022-007977-gr2.jpg

相似文献

1
First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative.作为输血替代品开发的血红蛋白囊泡作为人工红细胞的首次人体1期试验。
Blood Adv. 2022 Nov 8;6(21):5711-5715. doi: 10.1182/bloodadvances.2022007977.
2
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
JAMA. 2008 Sep 17;300(11):1297; author reply 1298-9. doi: 10.1001/jama.300.11.1297-a.
3
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
JAMA. 2008 Sep 17;300(11):1297-8; author reply 1298-9. doi: 10.1001/jama.300.11.1297-b.
4
The safety of hemoglobin blood substitutes.
Anesth Analg. 2004 Apr;98(4):1193. doi: 10.1213/01.ANE.0000110298.65918.E2.
5
Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions.基于血红蛋白的氧载体：关于输血替代品的研究与现状
Blood Transfus. 2010 Jun;8 Suppl 3(Suppl 3):s59-68. doi: 10.2450/2010.010S.
6
Artificial blood substitutes.人工血液替代品
Transfus Sci. 1992 Jul;13(3):357-70. doi: 10.1016/0955-3886(92)90148-A.
7
Polymer/hemoglobin assemblies: biodegradable oxygen carriers for artificial red blood cells.聚合物/血红蛋白组装体：用于人工红细胞的可生物降解氧载体。
Macromol Biosci. 2011 Jul 7;11(7):865-75. doi: 10.1002/mabi.201000469. Epub 2011 Feb 10.
8
Hemoglobin solutions--not just red blood cell substitutes.
Crit Care Med. 2000 Aug;28(8):3025-34. doi: 10.1097/00003246-200008000-00058.
9
Translational Research of Hemoglobin Vesicles as a Transfusion Alternative.血红蛋白囊作为输血替代品的转化研究。
Curr Med Chem. 2022;29(3):591-606. doi: 10.2174/0929867328666210412130035.
10
Synthesis and evaluation of a prototypal artificial red cell.
Science. 1985 Dec 6;230(4730):1165-8. doi: 10.1126/science.4071041.

引用本文的文献

1
Artificial cells and biomimicry cells: A rising star in the fight against cancer.人工细胞与仿生细胞：抗癌斗争中的一颗冉冉升起的新星。
Mater Today Bio. 2025 Apr 3;32:101723. doi: 10.1016/j.mtbio.2025.101723. eCollection 2025 Jun.
2
Advanced delivery systems for oxygen therapeutics: center around red blood cells.氧气治疗的先进输送系统：以红细胞为核心。
Ther Deliv. 2025 May;16(5):501-509. doi: 10.1080/20415990.2025.2475737. Epub 2025 Mar 9.
3
Therapeutic delivery of oxygen using artificial oxygen carriers demonstrates the possibility of treating a wide range of diseases.

本文引用的文献

1
Liposome-encapsulated hemoglobin (HbV) transfusion rescues rats undergoing progressive lethal 85% hemorrhage as a result of an anti-arrhythmogenic effect on the myocardium.脂质体包裹血红蛋白（HbV）输血可挽救因抗心律失常作用导致进行性致死性 85%出血的大鼠的生命。
Artif Organs. 2021 Nov;45(11):1391-1404. doi: 10.1111/aor.14033. Epub 2021 Jul 16.
2
Preparation of Artificial Red Blood Cells (Hemoglobin Vesicles) Using the Rotation-Revolution Mixer for High Encapsulation Efficiency.使用旋转-旋转混合器制备具有高包封效率的人工红细胞（血红蛋白囊泡）。
ACS Biomater Sci Eng. 2021 Jun 14;7(6):2835-2844. doi: 10.1021/acsbiomaterials.1c00424. Epub 2021 May 24.
3
使用人工氧载体进行氧的治疗性输送证明了治疗多种疾病的可能性。
J Nanobiotechnology. 2025 Jan 18;23(1):25. doi: 10.1186/s12951-024-03060-9.
4
Hemoglobin vesicles improve neurological outcomes after cardiac arrest in rats.血红蛋白囊泡可改善大鼠心脏骤停后的神经功能结局。
Resusc Plus. 2024 Nov 7;20:100819. doi: 10.1016/j.resplu.2024.100819. eCollection 2024 Dec.
5
Engineering Synthetic Erythrocytes as Next-Generation Blood Substitutes.工程合成红细胞作为下一代血液替代品
Adv Funct Mater. 2024 Jul 10;34(28). doi: 10.1002/adfm.202315879. Epub 2024 Feb 8.
6
Absence of Anaphylactic Reactions to Injection of Hemoglobin Vesicles (Artificial Red Cells) to Rodents.对啮齿动物注射血红蛋白囊泡（人工红细胞）未出现过敏反应。
ACS Omega. 2023 Dec 19;9(1):1904-1915. doi: 10.1021/acsomega.3c08641. eCollection 2024 Jan 9.
7
Recent advances in micro-sized oxygen carriers inspired by red blood cells.受红细胞启发的微型氧载体的最新进展。
Sci Technol Adv Mater. 2023 Jun 22;24(1):2223050. doi: 10.1080/14686996.2023.2223050. eCollection 2023.
8
Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023?血红蛋白类氧载体：2023 年的现状如何？
Medicina (Kaunas). 2023 Feb 17;59(2):396. doi: 10.3390/medicina59020396.
9
Research of storable and ready-to-use artificial red blood cells (hemoglobin vesicles) for emergency medicine and other clinical applications.用于急救医学及其他临床应用的可储存即用型人工红细胞（血红蛋白囊泡）的研究。
Front Med Technol. 2022 Dec 23;4:1048951. doi: 10.3389/fmedt.2022.1048951. eCollection 2022.
10
Examination of central nervous system by functional observation battery after massive intravenous infusion of carbon monoxide-bound and oxygen-bound hemoglobin vesicles in rats.在大鼠大量静脉输注一氧化碳结合型和氧结合型血红蛋白囊泡后，通过功能观察组合对中枢神经系统进行检查。
Curr Res Pharmacol Drug Discov. 2022 Oct 4;3:100135. doi: 10.1016/j.crphar.2022.100135. eCollection 2022.
Safety profile of high molecular weight polymerized hemoglobins.
高分子量聚合血红蛋白的安全性特征。
Transfusion. 2021 Jan;61(1):212-224. doi: 10.1111/trf.16157. Epub 2020 Oct 26.
4
Contribution of long-chain fatty acid to induction of myeloid-derived suppressor cell (MDSC)-like cells - induction of MDSC by lipid vesicles (liposome).长链脂肪酸对髓系来源抑制细胞（MDSC）样细胞诱导的贡献——脂质囊泡（脂质体）对MDSC的诱导作用。
Immunopharmacol Immunotoxicol. 2020 Dec;42(6):614-624. doi: 10.1080/08923973.2020.1837866. Epub 2020 Nov 1.
5
Efficacy of resuscitative infusion with hemoglobin vesicles in rabbits with massive obstetric hemorrhage.血红蛋白囊复苏输注对大量产科出血兔的疗效。
Am J Obstet Gynecol. 2021 Apr;224(4):398.e1-398.e11. doi: 10.1016/j.ajog.2020.09.010. Epub 2020 Sep 12.
6
Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs.脂质体诱导的过敏反应：通过设计安全的输注方案降低猪的风险。
J Control Release. 2019 Sep 10;309:333-338. doi: 10.1016/j.jconrel.2019.07.005. Epub 2019 Jul 8.
7
Blood Substitutes and Oxygen Therapeutics: A Review.血液代用品与氧气治疗学：综述
Anesth Analg. 2021 Jan;132(1):119-129. doi: 10.1213/ANE.0000000000003957.
8
Mechanisms of Toxicity and Modulation of Hemoglobin-based Oxygen Carriers.基于血红蛋白的氧载体的毒性机制及其调控。
Shock. 2019 Oct;52(1S Suppl 1):41-49. doi: 10.1097/SHK.0000000000001044.
9
Overview of Potential Clinical Applications of Hemoglobin Vesicles (HbV) as Artificial Red Cells, Evidenced by Preclinical Studies of the Academic Research Consortium.学术研究联盟的临床前研究证明血红蛋白囊泡（HbV）作为人工红细胞的潜在临床应用概述
J Funct Biomater. 2017 Mar 15;8(1):10. doi: 10.3390/jfb8010010.
10
Fluid resuscitation of hemorrhagic shock with hemoglobin vesicles in Beagle dogs: pilot study.比格犬失血性休克血红蛋白囊泡液体复苏的初步研究。
Artif Cells Blood Substit Immobil Biotechnol. 2012 Feb;40(1-2):179-95. doi: 10.3109/10731199.2011.637929.